供者CD34^(+)细胞纯化输注挽救治疗原发性骨髓纤维化异基因造血干细胞移植后移植物功能不良3例

Selected donor CD34^(+)cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis:3 cases report

回顾性分析上海市闸新中西医结合医院2020年至2023年行异基因造血干细胞移植(allo-HSCT)后发生移植物功能不良并接受供者CD34^(+)细胞纯化输注挽救治疗的3例原发性骨髓纤维化患者,其中男2例,女1例,中位年龄68(39~69)岁。启动供者CD34^(+)细胞纯化输注距allo-HSCT的中位时间为83(56~154)d。输注的纯化供者CD34^(+)细胞中位数7.67(7.61~9.06)×10^(6)/kg,CD34^(+)细胞纯度97.76%(96.50%~97.91%),回收率70%(42%~75%),2例获得血液学恢复。3例患者均未观察到急性GVHD,1例发生口腔慢性GVHD(中度)。供者CD34^(+)细胞纯化输注治疗原发性骨髓纤维化allo-HSCT后移植物功能不良有效且未观察到严重的急慢性GVHD。

A retrospective analysis was conducted on three patients with primary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation(allo-HSCT)at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from 2020 to 2023.They subsequently developed poor graft function.The patients received selected donor CD34^(+)cell boosts as salvage therapy.There were two male patients and one female patient,with a median age of 68(39-69)years.The median time from allo-HSCT to the selected donor CD34^(+)cell boost was 83(56-154)days.The median infusion of selected donor CD34^(+)cells was 7.67(7.61-9.06)×10^(6)/kg,with a CD34^(+)cell purity of 97.76%(96.50%-97.91%)and a recovery rate of 70%(42%-75%).Hematological recovery was achieved in two cases.No acute GVHD was observed in any of the three patients.One case of moderate oral chronic GVHD was noted.Selected donor CD34^(+)cell boosts for the treatment of poor graft function after allo-HSCT in primary myelofibrosis was effective and no severe acute or chronic GVHD was observed.